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Humans exhibit remarkable interindividual variations in the concentration of small molecules found
throughout the body, due in part to concurrent variations in each person’s associatedmicrobial communities.
Recent studies have begun to uncover how microbes interface with their host during exposure to drugs,
dietary compounds, and environmental toxicants, with broader implications regarding the causes and
consequences of biochemical individuality. Progress in this area will likely be an essential component of
personalized medicine and might be accelerated through the implementation of experimental designs and
theoretical principles honed through decades of work in the fields of toxicology and pharmacology.Reconsidering Biochemical Individuality
The concept of biochemical individuality, as proposed by Roger
J. Williams in 1956, was based on mounting evidence that the
variation in chemical composition and enzymatic activities be-
tween humans is so large, and so often uncorrelated, that it is
impossible to define a ‘‘normal’’ or ‘‘healthy’’ human (Williams,
1956). Therefore, one should consider that ‘‘practically every
human being is a deviate in some respects.’’ This observation
has profound and still-underappreciated implications for both
medicine and nutrition, emphasizing that interventions should
be tailored to the individual to ensure optimal efficacy and to
minimize side effects. This is perhaps most widely studied in
the context of pharmacology, where ‘‘variability in responses
to drugs has been observed as long as drugs have been tested
systematically’’ (Williams, 1956).
But what is responsible for such widespread variation be-
tween individuals? Two critical factors are host genetics and
nutritional status, although these often fail to explain the
observed interindividual variation in drug response (Ma and Lu,
2011). We propose that the human microbiome represents a
third and perhaps equally as important aspect of our biochemical
individuality, due to its remarkable variation even among clini-
cally healthy individuals; its contribution to the abundance, activ-
ity, and structure of metabolites throughout the body; and its
dynamic reconfiguration in response to numerous environmental
and host factors. We focus on microbial xenobiotic metabolism
as one important consequence of these variations, due to the
clinical relevance of drugs, dietary bioactive compounds, and
environmental toxicants, in addition to the broader impacts of
these pathways on host-microbial interactions and endogenous
compounds.
For the Microbiome, Variation Is the Norm
At a very coarse level, the gut microbiota of mammals, ranging
from the echidna to the elephant, looks similar, harboring bacte-
ria from the same dominant phyla: Firmicutes, Bacteroidetes,Proteobacteria, Actinobacteria, Verrucomicrobia, and Fusobac-
teria (Ley et al., 2008). However, increased resolution and depth
of sampling afforded by next-generation sequencing techniques
have emphasized the considerable diversity within each of these
phyla and the lack of a core gut microbiota—a consistent set of
abundant ‘‘species’’-level bacterial phylotypes across all or the
vast majority of people. It is possible to identify phylotypes that
are found in >50% of samples, but they can vary dramatically
in relative abundance (Huse et al., 2012; Tap et al., 2009; Turn-
baugh et al., 2009, 2010). Consistent with this finding, the
recently completed ‘‘Human Microbiome Project’’ found that
multiple body habitats exhibit marked variations in microbial
community structure despite restricting their sampling to young
adults from Missouri and Texas that were clinically screened for
an absence of disease (Consortium, 2012; Huse et al., 2012).
Considering recent evidence for geographical differences in
microbial community structure (Smith et al., 2013; Yatsunenko
et al., 2012), it seems likely that these studies vastly underesti-
mate the range of configurations possible.
These results question if it will be possible to ever define a
‘‘normal’’ or ‘‘healthy’’ microbiota. For other traits, like body
weight or height, individuals can be classified within the normal
range if they are between the 5th and 95th percentiles. It is diffi-
cult to directly apply these criteria to the gut microbiota due to
technical issues (data are typically measured in terms of relative,
not absolute, abundance) and biological limitations (phylotypes
are not normally distributed and fall below the limit of detection
in many individuals). With these caveats in mind, we sought to
determine how robust this standard definition of ‘‘normal’’ might
be when considering the gut microbiota.
We retrieved 16S rRNA gene sequencing data from fecal sam-
ples analyzed in the Human Microbiome Project (version 34)
(Consortium, 2012) from the QIIME database (Caporaso et al.,
2010). Each data set was subsampled to 5,000 sequences using
QIIME version 1.8.0 (n = 181 final samples; 1 sample/individual).
We then ranked each bacterial phylotype or taxonomic group byCell Metabolism 20, November 4, 2014 ª2014 Elsevier Inc. 761
Figure 1. Biochemical Individuality Viewed
through the Lens of Microbial Community
Structure
(A) The percentage of individuals categorized as
‘‘normal’’ declines rapidly as multiple species-
level phylotypes are considered. Expected values
were calculated using the formula 0.95Nwhere N is
the number of phylotypes.
(B) Similar trends were observed at taxonomic
levels from phylum to genus.
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ing from themost to least prevalent group, we ranked all samples
in order of abundance and retained them as ‘‘normal’’ if the
abundance of the current group was lower than the minimum
abundance in the top 5% of samples.
The percentage of individuals classified as normal decreased
rapidly with each additional bacterial phylotype, at a rate consis-
tent with a random selection of the 95th percentile in each round
(Figure 1A). We identified similar trends even after relaxing the
granularity of this analysis to higher-level taxonomic groups
(Figure 1B). Remarkably, after including just 13–14 phylotypes
(or taxa), only 50% of the individuals were consistently within
the normal range. These results are consistent with studies
demonstrating that the relative abundance of bacterial phylo-
types within the human gut microbiota are frequently
uncorrelated or display nonlinear relationships (Reshef et al.,
2011), resulting in a distinct subset of individuals that fall within
the normal range for each phylotype.
Attempts to characterize the gut microbiome using more
sophisticated computational methods have also emphasized
that there are multiple possible community structures. Compar-
ative analyses of multiple body habitats revealed smooth abun-
dance gradients of bacterial genera, with some signals of distinct
states (also referred to as community types) in the gut and vagina
(Ding and Schloss, 2014; Koren et al., 2013). Analysis of the
Danish gut microbiome revealed a bimodal distribution of ge-
netic diversity; individuals with a less diverse gut microbiome
were more likely to have increased adiposity and insulin resis-
tance (Le Chatelier et al., 2013).
However, these results also assume that the gut microbiota is
stable over time. Early studies using molecular fingerprinting
techniques suggested that the broad configuration of the gut
microbiota could be maintained for at least a year within an indi-
vidual (Zoetendal et al., 1998). These findings were confirmed in
studies using 16S rRNA gene sequencing techniques, demon-
strating that the gut microbiota was on average more similar
within rather than between individuals (Turnbaugh et al., 2009).
More recently, strain-level analyses of samples collected over
the course of 5 years have suggested that60%of themembers
of each individual’s gut microbiota may be stable for up to a
decade (Faith et al., 2013), and analyses of single nucleotide
polymorphisms in the gut microbiome suggest that individuals
may carry the same bacterial strain for at least a year (Schloiss-
nig et al., 2013).762 Cell Metabolism 20, November 4, 2014 ª2014 Elsevier Inc.But these analyses are to a large
degree based on the membership of a
given microbiota, not the relative abun-
dance of each taxonomic group. Studiesthat take relative abundance into account have shown marked
changes over time within each individual in multiple body habi-
tats: mouth (Caporaso et al., 2011), skin (Caporaso et al.,
2011), gut (David et al., 2014; Dethlefsen and Relman, 2011;
Stein et al., 2013; Walker et al., 2011), and vagina (Gajer et al.,
2012). These differences can in some cases be greater than
the pre-existing interindividual variations. Thus, these studies
suggest that the human microbiota is dynamic and can exist in
many configurations over a lifetime, consistent with studies of in-
fants (Dominguez-Bello et al., 2010; Koenig et al., 2011), preg-
nant women (Koren et al., 2012), and the elderly (Claesson
et al., 2012).
What is the functional relevance of these variations inmicrobial
community structure? Metagenomic analyses have revealed
that despite these differences in community structure, the rela-
tive abundance of many gene families and metabolic pathways
is surprisingly stable (Consortium, 2012; Kurokawa et al., 2007;
Turnbaugh et al., 2009). If gene abundance is predictive of
metabolic activity, one might conclude that this suggests the
presence of microbial ‘‘guilds’’ (Tscho¨p et al., 2009), in which
diverse assemblages can converge on the same overall meta-
bolic activity.
This guild theory, although still plausible, has been weakened
by metabolomic analyses of human samples, which demon-
strate that the concentration of microbial end products also
varies between individuals, especially in those of different age,
gender, race, or ethnicity (Wijeyesekera et al., 2012). Quantifica-
tion of the gut microbial cometabolites phenylacetylglutamine,
4-cresol sulfate, and hippuric acid in individuals from multiple
ethnic groups revealed marked variations both within and
between populations. For example, urinary levels of hippuric
acid were significantly lower in Japanese individuals. In a sepa-
rate study following 60 healthy men and women over a period of
30 days, hippuric acid was found to vary substantially, not only
between individuals but also over time (Saude et al., 2007).
Changes in hippuric acid concentration have been associated
with obesity, diabetes, atherosclerosis, and inflammatory bowel
disease (Lees et al., 2013), yet it remains unclear how changes to
the gut microbiome influence the production of this and other
related metabolites.
The case of hippuric acid is emblematic of the black box be-
tween variations in microbial community structure and function
(Figure 2A). Even in the case of the microbial metabolism of ther-
apeutic drugs, a fact that has been established for decades
Figure 2. Challenges and Complications to Our Understanding of
Microbial Metabolism
(A) Limited understanding of the links between microbial ecology (i.e., mem-
bership of a given community, the relative abundance of each member, and
their gene content) and metabolic activity (the functional output of a given
microbial community).
(B) Microbial (red), host (dark blue), and abiotic/environmental (green) factors
that are predicted to alter microbial xenobiotic metabolism.
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microbial mechanisms responsible and how they are altered by
various host, microbial, and environmental factors (Figure 2B).
In the next section, we discuss the potential for co-opting
approaches used in toxicology and pharmacology to develop a
more mechanistic understanding of microbial metabolism.
Learning from Classical Studies in Toxicology and
Pharmacology
Pharmacology, the study of drugs or chemicals, is one of the
oldest of the biological sciences. Similarly, toxicology, the study
of the adverse systemic effects of chemicals, is attributed to
Paracelsus, who wrote in 1567 about the occupational diseases
of miners and smelters (Frank et al., 2011). Comparatively,
microbial ecology is in its infancy: molecular methods for study-
ing complex microbial communities using the ribosomal RNA
gene were pioneered in the 1980s (DeLong et al., 1989; Fox
et al., 1980; Lane et al., 1985), and metagenomic methods
have risen to prominence in just the last decade (Schloss and
Handelsman, 2003). Furthermore, while metabolomics is
emerging from its probationary period to become a full-fledged
member of the -omics toolkit, a comprehensive annotation of
the microbial metabolome lags behind that of the host. There-
fore, although our appreciation of the chemical world is vast,
we know relatively little about how it influences, or is influenced
by, microbial communities.
The rich history of studies related to mammalian xenobiotic
metabolism provides a template with which to tackle the prob-
lem of microbial metabolism. Seminal work in this area has
generally involved the following pipeline: (step 1) identify a
biochemical transformation of interest, (step 2) reproduce the re-
action in vitro, (step 3) isolate the enzyme(s) responsible, and
(step 4) study the organs responsible and the subcellular location
of each reaction (Murphy, 2001). With these results as a founda-
tion, modern pharmacology aims to incorporate genetic poly-morphisms, drug-drug interactions, and environmental risk
factors to tailor a given treatment to each patient.
By contrast, we are at early days in terms of even cataloguing
the scope of microbial biotransformation in the human body.
Evidence indicates at least 44 drugs are directly metabolized
by the gut microbiome (see Haiser and Turnbaugh, 2013, for a
complete table), and a handful of others are thought to be indi-
rectly influenced by the gut microbiome (Bjo¨rkholm et al.,
2009; Clayton et al., 2009; Iida et al., 2013; Viaud et al., 2013).
Many of these reactions have been reproduced in vitro (Sousa
et al., 2008), but no systematic surveys have been performed
to see how many of the thousands of drugs and drug-like com-
pounds are influenced.
Furthermore, we know very little about the enzymes respon-
sible. Only three distinct enzymatic systems have strong links
to microbial drug metabolism (Haiser et al., 2013; Haiser and
Turnbaugh, 2013; Wallace et al., 2010), and only five have
been clearly linked to one or more taxonomic groups (Haiser
and Turnbaugh, 2013). In all of these cases, very little is known
about the phylogenetic distribution of these enzymes, the poten-
tial for horizontal gene transfer, and the subcellular location of
their activity. We also know very little about the precise location
along the gastrointestinal tract where these microbes are most
active and towhat degree the activities are luminal versusmucus
associated.
Understanding the links between microbial metabolism, host
genetic variation, drug-drug interactions, and environmental
factors will likely be difficult, if not impossible, without first
addressing these critical knowledge gaps. What is the full scope
of substrates that are subject to microbial metabolism, and what
are the common reactions? Do chemical or biophysical proper-
ties of small molecules influence their rate of microbial meta-
bolism? Can we reproduce these reactions in vitro, or will
some of them be driven by low abundance or difficult-to-culture
microbes? What are the main enzymes, microbial species, and/
or microbial consortia responsible? Where is this activity ex-
pressed relative to the cell of interest and the surrounding host
habitat? In the next section we briefly highlight some recent
studies that demonstrate the tools we now have in place to
answer some of these questions and to better understand the
implications of interindividual variations in microbial metabolism.
Interactions between the Gut Microbiome and
Xenobiotics
Although reciprocal interactions between gut microbes and
xenobiotics—including therapeutic drugs, antibiotics, dietary
bioactive compounds, and environmental toxins—have been
appreciated for decades, recent studies have just begun to
emphasize how elucidating the microbial mechanisms respon-
sible can provide novel insights. Here, we focus on recent evi-
dence that the gut microbiome mediates the metabolic effects
of drugs and environmental toxicants, as other recent reviews
have provided a more in-depth view of the historic and current
literature on drug and dietary bioactive metabolism (Carmody
and Turnbaugh, 2014; Haiser and Turnbaugh, 2012, 2013; Sousa
et al., 2008). For example, metabolomic analysis of samples
collected from patients treated with the HMG-CoA reductase
inhibitor simvastatin revealed that the pretreatment levels of mi-
crobial secondary bile acids predicted interindividual variationsCell Metabolism 20, November 4, 2014 ª2014 Elsevier Inc. 763
Figure 3. Microbiome-Dependent
Mechanisms May Alter the Metabolic
Outcomes of Diverse Therapeutics
Examples include (A) the cardiac drug simvastatin,
(B) the antipsychotic olanzapine, (C) the diabetes
medication metformin, and (D) the antioxidant
tempol. Abbreviations: Akkermansia muciniphila
(Akk), AMP-activated protein kinase (AMPK),
Bacteroidetes (Bact), b-muricholic acid (bMCA),
Farnesoid X receptor (FXR), Firmicutes (Firm),
glucose (Glc), gut microbiota (GM), 3-hydroxy-3-
methyl-glutaryl-CoA reductase (HMGCR), low-
density lipoprotein (LDL), primary bile acids
(1 BA), secondary bile acids (2 BA), and tauro-
b-muricholic acid (TbMCA).
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2011) (Figure 3A). These emerging links might have been ex-
pected given evidence that the mammalian gut microbiome
can influence both energy intake and expenditure (Ba¨ckhed
et al., 2004; Greenblum et al., 2012; Koren et al., 2012; Le Cha-
telier et al., 2013; Ridaura et al., 2013; Turnbaugh et al., 2006;
Vijay-Kumar et al., 2010) as well as diabetes risk (Karlsson
et al., 2013; Qin et al., 2012; Wen et al., 2008).
Use of the antipsychotic olanzapine is linked to multiple meta-
bolic side effects, including weight gain, increased visceral fat,
and glucose dysregulation, likely contributing to type 2 diabetes
and cardiovascular disease (Newcomer, 2004). While the mech-
anisms responsible are not fully understood, a recent study in
which rats were administered olanzapine in the presence or
absence of a cocktail of broad-spectrum antibiotics provided
preliminary evidence that a microbiota-dependent mechanism
may exist (Davey et al., 2013) (Figure 3B). Exposure to antibiotics
suppressed the Firmicutes phylum and increased the relative
abundance of Bacteroidetes while at the same time ameliorating
the olanzapine-induced weight gain, uterine fat deposition,
plasma free fatty acid levels, and macrophage infiltration of
adipose tissue.
Evidence is also building that the mechanism of action for the
antidiabetic (glucose-lowering) drug metformin may be in part
due to its impact on the gut microbiome (Figure 3C). Elegant
studies in the worm, Caenorhabditis elegans, demonstrated
that metformin alters pathways for folate and methionine meta-
bolism in their microbial food source (Escherichia coli), contrib-
uting to increased lifespan in the host organism (Cabreiro
et al., 2013). Metformin also alters the murine gut microbiota,
increasing the abundance of the mucin-degrading Akkermansia
genus, likely due to an elevation in the number of mucin-produc-
ing goblet cells (Shin et al., 2014). Colonization of mice with
Akkermansia in the absence ofmetformin reduced glucose levels
(Shin et al., 2014), consistent with previously published results
(Everard et al., 2013). Furthermore, a metagenomic analysis of
European women with normal, impaired, or diabetic glucose
control revealed a significant association between metformin
use andmultiple bacteria (Karlsson et al., 2013), although treated
individuals surprisingly demonstrated increased levels of Enter-
obacteriaceae (including Escherichia) and decreased levels of
Clostridium and Eubacterium. No differences in Akkermansia
were reported. Additional studies are necessary to clarify the
mechanisms by which metformin alters the mammalian gut
microbiota and how this altered microbial community might
impact glucose homeostasis.764 Cell Metabolism 20, November 4, 2014 ª2014 Elsevier Inc.Recent studies also suggest that the antioxidant tempol (4-hy-
droxy-2,2,6,6-tetramethylpiperidine 1-oxyl) reduces host adi-
posity and insulin resistance in part due to altering the interaction
between the gut microbiota and the nuclear receptor farnesoid X
receptor (FXR) (Li et al., 2013) (Figure 3D). Administration of tem-
pol to mice decreased the abundance of Lactobacillus spp.
(members of the Firmicutes phylum) and its bile salt hydrolase
activity (BSH), thus enriching levels of several FXR antago-
nists—namely tauro-b-muricholic acid (Sayin et al., 2013). While
we know that BSH activity contributes to enterohepatic circula-
tion of bile acids and may have cholesterol-lowering benefits to
the host, its purpose from the perspective of Lactobacillus spp.
and other BSH-encoding bacteria remains unclear (Moser and
Savage, 2001). Additional studies are needed to understand if
tempol is directly targeting Lactobacillus spp. or acting indirectly
via the host or other members of the gut microbiota. Of note, a
recent human study demonstrated that the oral antibiotic vanco-
mycin suppresses members of the Firmicutes phylum, alters bile
acid pools, and improves peripheral insulin sensitivity (Vrieze
et al., 2014). FXR signaling has also been recently implicated in
the metabolic effects of bariatric surgery (Ryan et al., 2014).
The microbial contributions to the metabolic effects of these
small molecules are likely just the tip of the iceberg. Numerous
environmental toxicants have been linked to obesity in epidemi-
ological studies and animal models (Snedeker and Hay, 2012),
and the gut microbiota has been implicated in the renal toxicity
of the industrial chemical melamine (Zheng et al., 2013). Given
that the major route of exposure to these compounds is through
the diet, the gut microbiota is exposed, in some case chronically.
The Roman philosopher Lucretius stated that ‘‘what is food to
one is to others bitter poison,’’ and while this statement is gener-
ally attributed to host toxicity, it seems prudent to begin to
consider microbial cell damage and community structure/func-
tion as a piece of the overall toxicological response. While some-
what tongue in cheek, the American Council on Science and
Health’s ‘‘Holiday Dinner Menu’’ lists carcinogens that, when
given in large amounts, can cause cancer in rodents. But how
these ‘‘safe’’ doses interact with the gut microbiota remains to
be determined. For example, arsenic in the drinking water alters
gutmicrobial community structure andmultiplemicrobial comet-
abolites (Lu et al., 2014a). These alterations to the gut microbiota
may contribute to interindividual variations in arsenic meta-
bolism and toxicity (Lu et al., 2014b). Clearly, more work is
necessary to better understand and characterize the impacts
of other diet-derived toxicants on our associated microbial
communities.
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Metabolism and Resistance
One of the long-standing criticisms of studying xenobiotics is
that they are by definition compounds foreign to living systems.
Why would our associated microbial communities evolve intri-
cate (and energetically costly) molecular mechanisms to metab-
olize or otherwise resist the toxic effects of small molecules that
they would not have been consistently exposed to in vivo? If ex-
posures are rare but highly toxic, can natural selection provide
sufficient protection against future exposures? This apparent
paradox has been pondered for centuries in the context of our
own human enzymes and can be resolved in part by considering
the known mechanisms for eukaryotic xenobiotic metabolism.
According to Klaassen, ‘‘In general, xenobiotic biotransforma-
tion is accomplished by a limited number of enzymes with broad
substrate specificities’’ (Klaassen et al., 2013). This comes at a
cost of enzymatic efficiency; for example, the cytochrome
P450s are catalytically versatile but have slow rates of substrate
turnover relative to most other enzymes.
Applying this logic to the human microbiome, one might
expect to find enzymes that have chosen a similar type of
‘‘generalist’’ strategy, allowing them to accept a wide diversity
of related substrates. Evidence in support of this hypothesis
comes from all three identified enzyme families for microbial
drug metabolism: (1) the b-glucuronidases, (2) the azo reduc-
tases, and (3) the cardiac glycoside reductases (cgr operon).
b-glucuronidases are a widely distributed family of enzymes
found in multiple bacterial phyla common to the human gut (Hai-
ser and Turnbaugh, 2013). Interest in their distribution and cata-
lytic activity has increased lately due to their contributions to the
dose-limiting side effects of multiple medications (LoGuidice
et al., 2012; Saitta et al., 2014; Wallace et al., 2010), yet these
same enzymes also contribute to the enterohepatic circulation
of bile acids and the sex hormone estrogen (Flores et al.,
2012). Given the vast diversity of compounds that are conju-
gated to glucuronic acid during phase II drugmetabolism (Klaas-
sen et al., 2013), it is likely that these enzymes have broad
specificity for many classes of compounds. The bacterial azo re-
ductases have a similarly wide distribution among bacterial
phyla (Haiser and Turnbaugh, 2013) and can act on therapeutic
drugs (e.g., sulfasalazine), in addition to many other azo linkage
(N-N double bond)-containing compounds, including common
dyes and pigments (Feng et al., 2012). However, it is unclear if
there are any endogenous substrates that can be metabolized
by these enzymes.
Recent studies have elucidated the inactivation of the cardiac
drug digoxin by the gut Actinobacterium Eggerthella lenta (Hai-
ser et al., 2013), a topic that has been discussed extensively
elsewhere (Haiser et al., 2014). Briefly, a two-gene operon en-
coding predicted bacterial cytochromes—the cardiac glycoside
reductase (cgr) operon—is induced by digoxin, unique to strains
capable of reduction, and predictive of digoxin reduction during
the in vitro incubation of human fecal microbial communities.
Furthermore, this activity can be suppressed by elevated dietary
protein, due to increased concentrations of arginine in the lumen
of the gastrointestinal tract (Haiser et al., 2013).
The cardiac glycoside reductase operon may also be able to
reduce compounds similar to digoxin, although this remains to
be directly demonstrated. Preliminary structure-function ana-lyses have shown that the expression of the cgr operon is
induced by multiple cardiac glycosides (digoxin, digitoxin, di-
goxigenin, and ouabain) (Haiser et al., 2013). Furthermore, struc-
tural predictions of Cgr2 revealed significant homology to a
fumarate reductase from Desulfovibrio vulgaris (Haiser et al.,
2014). Fumarate is chemically similar to the unsaturated lactone
ring of digoxin, suggesting that the cgr operon may have diversi-
fied to reduce the more exotic cardiac glycosides in addition to
endogenous substrates like fumarate.
There is also the distinct possibility that pathways for microbial
xenobiotic metabolism and resistance may evolve in other envi-
ronments and then be ‘‘horizontally transferred’’ to our resident
gut microbes. This is well known in the case of antibiotic-resis-
tance genes (Smillie et al., 2011) but may also be true for en-
zymes for xenobiotic metabolism. The first clear example of
this phenomenon was demonstrated for the marine bacterium
Zobellia galactanivorans, which encodes enzymes capable of
metabolizing the sulphated polysaccharide porphyran found in
marine algae, but not in terrestrial plants (Hehemann et al.,
2010). A homologous polysaccharide utilization loci (PUL) indic-
ative of horizontal gene transfer was found in the gut bacterium
Bacteroides plebeius and shown to be enriched in Japanese
populations, suggesting that these genes could have been trans-
ferred during exposure to marine bacteria found on nonsterile
seaweed commonly used in sushi. More recently, experimental
support was provided to support the inferred porphyranase
activity of this PUL in the gut microbiome (Hehemann et al.,
2012). Porphyran uniquely supported the growth of B. plebeius
and induced the expression of the identified PUL. Genomic anal-
ysis demonstrated that the PULwas located in an integrative and
conjugative element, suggestive of horizontal gene transfer.
Given the prevalence of horizontal gene transfer in the gastroin-
testinal tract (Smillie et al., 2011), the long-standing and diverse
portfolio of antibiotic resistance genes in the environment
(Wright, 2007), and our exposure to diet-derived microbes from
multiple domains of life (bacteria, fungi, and viruses) that resist
digestion (David et al., 2014), it seems likely that these sorts of
genetic ‘‘donations’’ to the microbiome are happening far more
frequently than we currently appreciate.
Moving toward Personalized Medicine and Nutrition
Despite encouraging first steps, we have only just begun to
uncover the many links between our associated microbial
communities and our biochemical individuality. It is becoming
increasingly clear that microbial metabolism plays a key role in
pharmacology and nutrition, but it remains challenging to relate
interindividual variations in microbial community structure to
metabolic rate, even in the context of well-studied pathways
like anaerobic fermentation. The net result of these ongoing
studies promises to redefine what we think of ‘‘health’’ while
also shedding new light on chronic diseases including metabolic
syndrome (Ridaura et al., 2013), cardiovascular disease (Koeth
et al., 2013), cancer (Kostic et al., 2013), and perhaps even
behavioral disorders (Hsiao et al., 2013).
Althoughmany efforts are currently underway to develop novel
microbiome-based therapies (Olle, 2013), it will also be critical to
utilize both model systems and human studies to explore the
myriad host, microbial, and environmental factors that shape
each individual’s metabolic profile. These efforts will likely beCell Metabolism 20, November 4, 2014 ª2014 Elsevier Inc. 765
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microbial genes andmetabolic pathways responsible for xenobi-
otic metabolism, and the degree to which they act independently
of the broader community context. To aid in this endeavor, a pro-
ductive unionmight be formed between toxicologists who have a
deep understanding of the host and environmental factors
contributing to toxicity and microbiologists interested in how
microbial communities shape their host. By working together, it
may be possible to finally resolve long-standing questions about
the sources of interindividual variation in response to therapeutic
or dietary interventions, with the goal of someday providing indi-
vidualized recommendations that capitalize on, instead of
ignore, our idiosyncratic metabolisms.
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